FCGR2A and neoplasm: Using human FcγR-transgenic mice, Arce Vargas et al. clearly demonstrated that antibodies with isotypes equivalent to ipilimumab increased the CD8+ to Treg ratio by depleting intra-tumoral Tregs to promote tumor rejection (15).